

Pan European patient group funding

PHA Europe – Pulmonary Hypertension Association

PHA Europe is the umbrella organization for national associations of patients living with pulmonary hypertension (PH) in Europe. PHA Europe works together with its members to enhance awareness of PH across Europe, promote optimal standards of care for people living with the disease, ensure the availability of all approved treatments and encourage research for new medicines and therapies.

We have supported this group since 2007.

During 2019:

 GSK provided a sponsorship of €37,375 to support PHA Europe in their Capacity Building Program which covers three activities, namely the Annual European Pulmonary Hypertension Conference, the "White Spots Program" and Fellowship program. Further information may be found here: https://www.phaeurope.org/projects-activities/capacity-building/

Our support represented 7% of their overall income.

During 2017:

 GSK provided an unrestricted grant of €80,000 to support the group in delivering three separate activities: Annual European Pulmonary Hypertension Conference, "White Spots" and Organization Development Program and Fellowship program.

Our support represented 12% of their overall income.

During 2016:

 GSK provided an unrestricted grant of €52,000 to support the group in delivering three separate activities: the Annual PH Europe Conference which took place 14-18th September in Barcelona, World PH Day on the 5th of May and the development of the bi-annual PHA Europe Journal.

Our support represented 8% of their overall income.

During 2015:

• We gave an unrestricted grant of £85,000 to PHA-Europe to support in the delivery of their objectives.

Our support represents 12% of their overall income.

During 2014:

 We gave an unrestricted grant of £53,000 PHA-Europe to support in the delivery of their objectives.

Our support represents 6% of their overall income.

During 2013:

 GSK has provided an unrestricted grant of £28,000 for the organization of the PHA-Europe Annual Leaders Meeting and General Assembly on 11th -15th September 2013, Castelledefels, Spain.

Our support represents 4.3 % of their overall income.

During 2012:

• We gave an unrestricted grant of £27,000 for the Annual Leaders Meeting and General Assembly on 3rd September 2012 in Vienna.

Our support represents 5% of their overall income.

During 2011:

- We gave an unrestricted grant of €30,000 as core support for 2011 to help them with their activities.
- In addition we gave an unrestricted grant of 10,000 euro for a meeting of the Pulmonary Expert Roundtable on 26th September in Amsterdam.

Our support represented 5% of their overall income.

During 2010:

- We gave an unrestricted grant of €1000 to help support the attendance and participation of the Vice President to share the patient's perspective of living with PHA at a medical congress in Bologna, Italy in June.
- In addition, we gave an unrestricted grant of €10,000 to help support the development of an interactive website to ensure accurate information about pulmonary hypertension for patients.
- Finally, we gave an unrestricted grant of €30,000 as core support for 2011 to help them with their activities.

Our support represented 23% of their overall income.

During 2008:

We gave an unrestricted grant of €10,000 to help them with their activities.

Our support represented 60% of their overall income.